维得利珠单抗治疗中重度溃疡性结肠炎的疗效观察

Clinical Efficacy of Vederizumab in Treatment of Moderate to Severe Ulcerative Colitis

目的:观察维得利珠单抗治疗中重度溃疡性结肠炎患者的疗效。方法:将我院2020年1月至2022年12月收治的102例中重度溃疡性结肠炎患者随机分为治疗组和常规组,每组51例。常规组患者予以免疫抑制剂加糖皮质激素治疗,治疗组患者予以维得利珠单抗治疗,比较2组患者治疗12周后的临床疗效、肠黏膜指标水平、肠道屏障功能及不良反应发生率。结果:治疗组患者临床总有效率高于常规组(P<0.05);治疗前2组患者血清三叶因子3(TFF3)、表皮生长因子受体(EGFR)水平比较差异无统计学意义(P>0.05),治疗后2组患者肠黏膜TFF3、EGFR水平均高于治疗前,且治疗组高于常规组(P<0.05);治疗前2组患者血清二胺氧化酶(DAO)、D-乳酸(D-LA)水平比较差异无统计学意义(P>0.05),治疗后2组患者血清DAO、D-LA水平均降低(P<0.05),且治疗组低于常规组(P<0.05);2组患者不良反应发生率比较差异无统计学意义(P>0.05)。结论:维得利珠单抗治疗中重度溃疡性结肠炎,可有效改善患者临床症状,提高肠黏膜EGFR和TFF3表达水平,调节肠道屏障功能,临床疗效较佳且安全性良好。

Objective To observe the clinical efficacy of Vederizumab in the treatment of moderate to severe ulcerative colitis.Methods Total 102 patients with moderate to severe ulcerative colitis admitted to our hospital from January 2020 to December 2022 were randomly divided into the treatment group and the routine group,with 51 patients in each group.Patients in the routine group were treated with immunosuppressant and glucocorticoid,while patients in the treatment group were treated with vederizumab.The clinical efficacy,intestinal mucosal indexes,intestinal barrier function and incidence of adverse reactions were compared between the two groups after 12 weeks of treatment.Results The total effective rate of the treatment group was higher than that of the routine group(P<0.05).There was no significant difference in serum levels of trefoil factor 3(TFF3)and epidermal growth factor receptor(EGFR)between the two groups before treatment(P>0.05).After treatment,the serum levels of intestinal mucosa TFF3 and EGFR in both groups were higher than before treatment,and were higher in the treatment group than in the routine group(P<0.05).There was no significant difference in serum levels of diamine oxidase(DAO)and D-lactic acid(D-LA)between the two groups before treatment(P>0.05).After treatment,serum levels of DAO and D-LA were decreased(P<0.05),and were lower in the treatment group than in the routine group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion In the treatment of moderate to severe ulcerative colitis,Vederizumab can effectively improve the clinical symptoms of patients,increase the expression levels of EGFR and TFF3 in intestinal mucosa,and regulate the intestinal barrier function,with good clinical efficacy and safety.